REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

This early-phase study tests a combination of three drugs (alisertib, bortezomib, and rituximab) in adults with mantle cell or low-grade non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose of the two newer dru…

This study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than RCHOP alone. About 43 adults with advanced or returning lymphoma are ta…

This study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…

This study tests whether adding the drug acalabrutinib to a CAR T-cell therapy called liso-cel can help people with aggressive B-cell lymphoma that has come back or not responded to treatment. About 28 adults will receive the combination and be monitored for tumor shrinkage and s…

This phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…

This study tests whether combining two immune-boosting drugs, epcoritamab and lenalidomide, can shrink or eliminate lymphoma in 34 patients whose cancer did not respond to prior treatment or came back. The participants have a type of lymphoma linked to a weakened immune system, s…

This early-phase study tests the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The drugs work by blocking cancer cell survival s…

This early-stage trial is testing a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and to see if the combination can shrink tumors. About 48…

This study follows about 150 people who have already received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to track any long-term side effects for up to 15 years after treatment. No new treatments are given—just regular check-ups to monitor safety…